Gloom Amidst Contract Research Boom
This article was originally published in PharmAsia News
Executive Summary
According to conservative estimates, China's contract research organization market has hit 4 billion yuan and is expanding at 100 percent annually. However, the breakneck development is curtailed by the shortage of talent with practical experience, high investments in research facilities, and ignorance on intellectual property rights. Industry experts suggest that domestic CROs can succeed only when they ensure international-level education and training, proper legal structure, and focused marketing development. They should also form a more competitive local team and concentrate on early stage drug development, as well as preclinical and Phase I and II clinical trials to take advantage of domestic resources. (Click here for more)
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.